Adaptimmune Therapeutics PLC (ADAP)
0.6206
-0.02
(-2.51%)
USD |
NASDAQ |
Nov 22, 10:34
Adaptimmune Therapeutics Total Liabilities (Quarterly): 237.45M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 237.45M |
| June 30, 2024 | 225.43M |
| March 31, 2024 | 233.64M |
| December 31, 2023 | 243.10M |
| September 30, 2023 | 208.51M |
| June 30, 2023 | 216.33M |
| March 31, 2023 | 204.20M |
| December 31, 2022 | 247.04M |
| September 30, 2022 | 218.86M |
| June 30, 2022 | 246.35M |
| March 31, 2022 | 256.65M |
| December 31, 2021 | 263.58M |
| September 30, 2021 | 112.54M |
| June 30, 2021 | 111.85M |
| March 31, 2021 | 102.42M |
| December 31, 2020 | 109.92M |
| September 30, 2020 | 102.82M |
| June 30, 2020 | 104.62M |
| March 31, 2020 | 99.20M |
| Date | Value |
|---|---|
| December 31, 2019 | 57.90M |
| September 30, 2019 | 60.57M |
| June 30, 2019 | 52.53M |
| March 31, 2019 | 50.78M |
| December 31, 2018 | 29.85M |
| September 30, 2018 | 33.47M |
| June 30, 2018 | 46.20M |
| March 31, 2018 | 55.81M |
| December 31, 2017 | 78.16M |
| September 30, 2017 | 72.39M |
| June 30, 2017 | 54.78M |
| March 31, 2017 | 57.65M |
| December 31, 2016 | 68.37M |
| September 30, 2016 | 42.64M |
| June 30, 2016 | 42.57M |
| March 31, 2016 | 42.61M |
| September 30, 2015 | 46.63M |
| December 31, 2014 | 45.85M |
| June 30, 2014 | 53.11M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
57.90M
Minimum
Dec 2019
263.58M
Maximum
Dec 2021
180.12M
Average
212.42M
Median
Total Liabilities (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | 6.628M |
| NuCana PLC | 20.58M |
| Autolus Therapeutics PLC | 350.52M |
| Bicycle Therapeutics PLC | 165.71M |
| TC BioPharm (Holdings) PLC | 7.807M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 317.44M |
| Shareholders Equity (Quarterly) | 79.99M |
| Debt to Equity Ratio | 0.6234 |
| Current Ratio | 3.848 |
| Net Debt Paydown Yield | -4.10% |